{"nctId":"NCT00078286","briefTitle":"Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure","startDateStruct":{"date":"2003-11"},"conditions":["Heart Failure, Congestive","Chronic Heart Failure","Depression"],"count":469,"armGroups":[{"label":"Sertraline","type":"EXPERIMENTAL","interventionNames":["Drug: Sertraline"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sertraline","otherNames":["Zoloft"]},{"name":"Placebo","otherNames":["Inactive pill"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chronic heart failure\n* Diagnostic and Statistical Manual- Fourth Edition (DSM-IV) criteria for major depression\n* Current use of any antipsychotic medication at study entry\n\nExclusion Criteria:\n\n* Life-threatening comorbidity with a 50% or higher likelihood of death within 1 year\n* History of psychoses, bipolar disorder, or severe personality disorder\n* History of alcohol or drug dependence in the last year\n* Severe physical disability that may interfere with the study\n* Neurological impairment\n* Active suicidal ideations\n* Current use of antidepressant medication(s) at the start of study medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Symptoms of Depression in Congestive Heart Failure Patients With Clinical Depression After Treatment With Sertraline or Placebo","description":"Symptoms of depression (as measured by the Hamilton Depression Rating Scale, HDRS) in congestive heart failure patients with clinical depression after treatment with sertraline or placebo.\n\nThe 17-item Hamilton Depression Rating Scale (HDRS) is a rater-administered assessment of depression severity, with total score ranges from 0 (not at all depressed) to 52 (most severely depressed). Change in depression was measured as the difference between the 12-week HDRS scores and the baseline HDRS scores. Thus, a negative value reflects an improvement in depressive symptoms over the 12-week period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"0.5"},{"groupId":"OG001","value":"-6.8","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Cardiac Events and Morbidity / Mortality, Including Rehospitalization, in Congestive Heart Failure Patients With Depression After Treatment With Sertraline or Placebo.","description":"Composite cardiovascular scores are calculated for each participant using recorded cardiac events, morbidity/mortality, rehospitalization, and discontinuation due to cardiovascular events. Composite score is compared for sertraline and placebo treatment groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.6","spread":null},{"groupId":"OG001","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":null},{"groupId":"OG001","value":"25.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":57,"n":234},"commonTop":["Congestive Heart Failure","Other Cardiovascular","Unstable Angina"]}}}